NeoImmuneTech, Inc. (950220.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩1,670 (+3.99%) as of
Key statistics
- Market cap
- 55.99B
- Dividend yield
- 0.00%
- 52-week range
- 1,115.00 – 4,450.00
- Beta
- 0.54
- Revenue (TTM)
- 1.76B
- Profit margin
- 0.00%
- Volume
- 155.70k
About NeoImmuneTech, Inc.
NeoImmuneTech, Inc., a clinical-stage T cell-based biotechnology company, develops and sells immuno-therapeutics in Korea. It is developing NT-I7, an IL-7 class T- cell amplifier to treat acute radiation syndrome; and Heterodimer hybrid Fc platform, an antibody platform technology, as well as NT2020, a T cell activator; NT3020, a T cell engager; NT4010, an advanced CAR-T; and NT5010, a TME modifier. The company was incorporated in 2014 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Rockville, MD, United States
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.